Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease

J Pediatr Hematol Oncol. 2023 Jul 1;45(5):e621-e623. doi: 10.1097/MPH.0000000000002623. Epub 2023 Jan 12.

Abstract

Progressive familial intrahepatic cholestasis type 1 (PFIC1) is an inherited, progressive cholestatic liver disease. Here, we present an approach to the treatment of Ewing sarcoma in a patient with PFIC1. The diagnosis of PFIC1 presents a unique challenge in the treatment of Ewing sarcoma, as the standard-of-care vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide chemotherapy backbone for Ewing sarcoma therapy treatment relies heavily on intact hepatic metabolism. In addition, we report prolonged lymphopenia and severe infectious complications in this patient, both of which may be attributed to more severe immunosuppression in setting of poor hepatic metabolism of chemotherapeutic agents.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Neoplasms* / drug therapy
  • Cholestasis*
  • Cholestasis, Intrahepatic*
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Humans
  • Ifosfamide
  • Sarcoma, Ewing* / drug therapy
  • Vincristine / therapeutic use

Substances

  • Cyclophosphamide
  • Etoposide
  • Ifosfamide
  • Doxorubicin
  • Vincristine

Supplementary concepts

  • Cholestasis, progressive familial intrahepatic 1